Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | TSPO | P30536 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3393849 | 0.84 | OPRM1 (0.43) | HPGDALDH1A1NPC1HTTRAB9A | |
| SCHEMBL976922 | 0.80 | ALDH1A1 (0.39) | HPGDALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL761128 | 0.78 | TSHR (0.45) | HPGDALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL4351294 | 0.78 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL7258846 | 0.77 | CA2 (0.40) | HPGDALDH1A1SMN1; SMN2HTTGAA | |
| SCHEMBL4355633 | 0.77 | PDK1 (0.43) | — | |
| SCHEMBL4347110 | 0.77 | EGFR (0.43) | TRPM8ALDH1A1NPC1RAB9AGAA | |
| SCHEMBL4347969 | 0.77 | EGFR (0.43) | ALDH1A1NPC1RAB9AGAALMNA | |
| SCHEMBL2504679 | 0.77 | AOC3 (0.41) | TRPM8HPGDALDH1A1NPC1HTT | |
| Hydrochloric Acid SCHEMBL7656186 | 0.76 | PTPN1 (0.41) | HPGDALDH1A1SMN1; SMN2HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249075-A1 | C11 Modified Retrosteroids as Progesterone Receptor Modulator Compounds | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| WO-2008113851-A2 | NOVEL C11 MODIFIED RETROSTEROIDS AS PROGESTERONE RECEPTOR MODULATOR COMPOUNDS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249075-A1 | C11 Modified Retrosteroids as Progesterone Receptor Modulator Compounds | HSD17B11, CYP19A1, ESRRA | TRPM8 3255/4885HPGD 373/4885ALDH1A1 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.